Published in AIDS Weekly, August 5th, 1996
"The interest in this disease area within the pharmaceutical industry is very high," said Paul Haycock, M.D., Cantab. "We have been in discussions with several major companies about TA-GW, but SBBio's experience and commitment to novel vaccine development, both for therapy and prophylaxis, their expertise with new adjuvants, and their specialized global marketing infrastructure combine to make them a highly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.